Clinical Trials in Jeffersonville, Indiana
9 recruiting
Showing 1–9 of 9 trials
Recruiting
Phase 2
Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer
Low-grade NMIBCFGFR Gene AmplificationFGFR Gene Alterations+3 more
Tyra Biosciences, Inc90 enrolled29 locationsNCT06995677
Recruiting
Phase 3
A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer
Non-Muscle Invasive Bladder Neoplasms
Janssen Research & Development, LLC641 enrolled193 locationsNCT06319820
Recruiting
Phase 3
A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Prostate Cancer
AstraZeneca700 enrolled328 locationsNCT06952803
Recruiting
Phase 2
A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer
Prostate Cancer
Debiopharm International SA66 enrolled37 locationsNCT06395753
Recruiting
Phase 1
A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer
Prostate CancerMetastatic Castration-resistant Prostate CancerMetastatic Castration-Sensitive Prostate Cancer
Astellas Pharma Global Development, Inc.174 enrolled25 locationsNCT04729114
Recruiting
Phase 2
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
High-risk Non-muscle Invasive Bladder Cancer
CG Oncology, Inc.325 enrolled65 locationsNCT06567743
Recruiting
Phase 2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Prostate Cancer
Astellas Pharma Global Development, Inc.900 enrolled241 locationsNCT02960022
Recruiting
Phase 2
Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Dendreon400 enrolled31 locationsNCT06134232
Recruiting
Phase 1
Study of ORIC-944 in Patients With Metastatic Prostate Cancer
Metastatic Prostate Cancer
ORIC Pharmaceuticals250 enrolled27 locationsNCT05413421